Biosensors employing a novel methylation gate and DNA nanocircuit enhance molecular imaging in live biological samples, indicating advances in disease diagnosis.
Fluorescent biosensors constructed from sensitive DNA nanocircuits for high-fidelity imaging in live biological samples are in high demand for disease diagnosis. In this contribution, we present a direct near-infrared (NIR) photocage-blocked methylation gate that integrates with an ultrasensitive triple-loop self-boosted exponential amplification DNA nanocircuit. For one thing, a methylation gate is incorporated as a specific component to enhance biorecognition capability, which is then directly blocked by an NIR photocage comprising an upconverting nanoparticle and a photolytic 6-nitropiperonyloxymethyl (NPOM) group. Under exogenous 980 nm NIR-light-transformed ultraviolet upconverting luminescence, the linkage between the NPOM group and adenine is photolytically cleaved to controllably expose the m⁶A site. For another, by cascading an iterative catalytic hairpin assembly hybridization chain reaction cycle with a self-actuated DNAzyme cleavage that triggers fluorescence output, a robust DNA nanocircuit with triple-loop self-boosted exponential amplification is built. When a model microRNA biomarker (miRNA-155) with elevated expression across various malignant tumors is used for proof-of-concept validation, we show the ultrahigh sensitivity and strong specificity of this fluorescent biosensor. More importantly, the bioanalytical toolbox enables high-fidelity molecular imaging in live-cell and in vivo scenarios, paving the way for the deployment of DNA nanocircuits in disease diagnosis.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: